Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Candel Therapeutics (CADL)
NASDAQ:CADL
RESEARCH TOOLSreports
Holding CADL?
Track your performance easily
CADL Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.66 - $14.30
Previous Close$5.51
Volume151.15K
Average Volume (3M)252.23K
Market Cap
$180.00M
Enterprise Value$176.78M
Total Cash (Recent Filing)$21.45M
Total Debt (Recent Filing)$18.56M
Price to Earnings (P/E)―
Beta-0.12
Next Earnings
Nov 07, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.70
Shares Outstanding32,084,777
10 Day Avg. Volume257,562
30 Day Avg. Volume252,230
Standard Deviation0.61
R-Squared0.00590
Alpha0.08
Financial Highlights & Ratios
Price to Book (P/B)-17.77
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-7.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-4.87
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Candel Therapeutics News
PremiumCompany Announcements
Candel Therapeutics Advances in Cancer Treatment Trials
Ownership Overview
26.58% Insiders
4.90% Mutual Funds
0.18% Other Institutional Investors
63.11% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CADL FAQ
What was Candel Therapeutics’s price range in the past 12 months?
Candel Therapeutics lowest stock price was $0.66 and its highest was $14.30 in the past 12 months.
What is Candel Therapeutics’s market cap?
Currently, no data Available
When is Candel Therapeutics’s upcoming earnings report date?
Candel Therapeutics’s upcoming earnings report date is Nov 07, 2024 which is in 9 days.
How were Candel Therapeutics’s earnings last quarter?
Candel Therapeutics released its earnings results on Aug 13, 2024. The company reported -$0.74 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.74.
Is Candel Therapeutics overvalued?
According to Wall Street analysts Candel Therapeutics’s price is currently Overvalued.
Does Candel Therapeutics pay dividends?
Candel Therapeutics does not currently pay dividends.
What is Candel Therapeutics’s EPS estimate?
Candel Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Candel Therapeutics have?
Candel Therapeutics has 32,084,778 shares outstanding.
What happened to Candel Therapeutics’s price movement after its last earnings report?
Candel Therapeutics reported an EPS of -$0.74 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 4.659%.
Which hedge fund is a major shareholder of Candel Therapeutics?
Among the largest hedge funds holding Candel Therapeutics’s share is Woodline Partners LP. It holds Candel Therapeutics’s shares valued at N/A.
---
Candel Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bearish
CADL Sentiment 100%
Sector Average 71%
Sector Average 71%
Insider Transactions
Sold Shares
Worth $442.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 4.2%
Last 30 Days ▼ 4.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
512.90%
12-Months-Change
Fundamentals
Return on Equity
-480.68%
Trailing 12-Months
Asset Growth
-54.89%
Trailing 12-Months
Company Description
Candel Therapeutics
Candel Therapeutics Inc is a late clinical stage biopharmaceutical company. It is focused on helping patients fight cancer with oncolytic viral immunotherapies.
---
CADL Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Adaptimmune Therapeutics
―
Bioxcel Therapeutics
―
Mereo Biopharma Group Plc
―
Kala Pharmaceuticals
―
Best Analysts Covering CADL
1 Year
1 Year Success Rate
4/5 ratings generated profit
1 Year Average Return
+386.24%
reiterated a buy rating 12 months ago
Copying Vernon Bernardino's trades and holding each position for 1 Year would result in 80.00% of your transactions generating a profit, with an average return of +386.24% per trade.
---